1. Indications and Usage
Tetanus Prophylaxis: Indicated for passive immunity to prevent tetanus infection in adult patients with traumatic wounds requiring passive immunization.
Usage Restrictions: Safety and efficacy in patients <18 years of age have not been established.
2. Dosage and Administration
Route of Administration: Intramuscular injection ONLY.
Recommended Dosage: 10 mg administered as a single dose.
Critical Administration Instructions:
Site: Inject into the gluteal muscle.
Administration: No reconstitution is required prior to administration.
3. Mechanism of Action
Neutralization: This recombinant humanized monoclonal antibody binds to the AB fragment of tetanus toxin.
Inhibition: It blocks the transport of the toxin and inhibits its proteolytic activity on VAMP-2 (vesicle-associated membrane protein), thereby providing passive immunity against tetanus.
4. Safety and Warnings
Hypersensitivity: Contraindicated in patients with known severe allergies to the active ingredient or other serious allergic history.
Immunogenicity: As with all therapeutic proteins, anti-drug antibodies may develop, though no neutralizing antibodies were observed in clinical trials.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Treatment-emergent adverse events (≥0.5%) include drug-related adverse events, elevated liver enzymes (ALT/AST), positive urine occult blood, elevated blood glucose, and injection site reactions (pain, erythema, numbness, swelling).
Clinical Research Highlights: In a Phase III trial comparing this drug to human tetanus immunoglobulin (HTIG) for trauma patients, no serious adverse events occurred in either group, demonstrating a favorable safety profile.
6. Drug Interactions
Tetanus Vaccines: Concomitant use with adsorbed tetanus vaccines may reduce the total exposure of this drug by approximately 14%.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Siltartoxatug.
Appearance: Solution.
Packaging: Single-dose vials (e.g., 10 mg/0.5 mL).
Storage: Store according to standard pharmaceutical guidelines for biological products (refer to specific package insert for precise conditions).

Xintituo Stelara Injection
Brand Name:新替妥 ®(Xintituo®)
Generic Name: Stelara
Strength: 10 mg per 0.5 mL vial, 1 vial per box
Manufacturer: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Marketing Authorization Holder: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Approval Date in China: February 11, 2025
Registration Number: 国药准字S20250012
Storage: Store and transport in the original package at 2–8°C, protected from light. Do not freeze or shake violently. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of Siltartoxatug(Xintituo)
Only logged in customers who have purchased this product may leave a review.





Reviews
There are no reviews yet.